246 related articles for article (PubMed ID: 33710617)
1. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.
Shimoyama S; Kawata K; Ohta K; Chida T; Suzuki T; Tsuneyama K; Shimoda S; Kurono N; Leung PSC; Gershwin ME; Suda T; Kobayashi Y
Eur J Immunol; 2021 Jun; 51(6):1519-1530. PubMed ID: 33710617
[TBL] [Abstract][Full Text] [Related]
2. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
3. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
[TBL] [Abstract][Full Text] [Related]
4. Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.
Saeki R; Ogino H; Kaneko S; Unoura M; Kobayashi K
J Gastroenterol; 1995 Dec; 30(6):739-44. PubMed ID: 8963391
[TBL] [Abstract][Full Text] [Related]
5. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
9. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid influences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis.
Milkiewicz M; Kopycińska J; Kempińska-Podhorodecka A; Haas T; Bogdanos DP; Elias E; Milkiewicz P
J Immunol Res; 2014; 2014():921285. PubMed ID: 24741631
[TBL] [Abstract][Full Text] [Related]
11. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
15. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
[No Abstract] [Full Text] [Related]
16. Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in patients with primary biliary ssscholangitis and inadequate response to Ursodeoxycholic acid: a pilot study.
Yang H; Yang H; Wang L; Shi H; Liu B; Lin X; Chang Q; Chen JDZ; Duan Z
BMC Complement Med Ther; 2020 Aug; 20(1):242. PubMed ID: 32738911
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
[TBL] [Abstract][Full Text] [Related]
18. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7.
Jiang X; Lian M; Li Y; Zhang W; Wang Q; Wei Y; Zhang J; Chen W; Xiao X; Miao Q; Bian Z; Qiu D; Fang J; Ansari AA; Leung PSC; Coppel RL; Tang R; Gershwin ME; Ma X
J Autoimmun; 2018 Jun; 90():64-75. PubMed ID: 29429758
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and Treatment of Primary Biliary Cholangitis].
Kim KA
Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
